SCHEMBL3237191

SCHEMBL3237191

CS(=O)(=O)Nc1ccc(NC(=O)c2ccc(O)c(O)c2)cc1O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TOP1 P11387 3/20 0.60
NPC1 O15118 2/20 0.51
HPGD P15428 1/20 0.50
TERT O14746 1/20 0.50
SNCA P37840 3/20 0.49
ALOX15 P16050 2/20 0.49
PTGS2 P35354 1/20 0.48
JAK3 P52333 1/20 0.48
KMT2A Q03164 1/20 0.48
RAB9A P51151 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
MAPT P10636 1/20 0.47
KDM4E B2RXH2 2/20 0.46
LMNA P02545 1/20 0.46
EP300 Q09472 1/20 0.46
KAT2B Q92831 1/20 0.46
KAT8 Q9H7Z6 1/20 0.46
TDP1 Q9NUW8 1/20 0.45
HTT P42858 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3247691 1.00 TOP1 (0.60) TOP1NPC1HPGDTERTSNCA
SCHEMBL3238696 0.96 NPC1 (0.54) TOP1NPC1HPGDSNCAKMT2A
SCHEMBL3236416 0.92 NPC1 (0.54) TOP1NPC1HPGDTERTSNCA
SCHEMBL3236934 0.92 NPC1 (0.51) TOP1NPC1HPGDALOX15KMT2A
SCHEMBL3236400 0.90 TOP1 (0.62) TOP1NPC1HPGDTERTSNCA
SCHEMBL12513288 0.90 TOP1 (0.58) TOP1NPC1HPGDTERTSNCA
SCHEMBL13907498 0.88 NPC1 (0.48) TOP1NPC1HPGDALOX15KMT2A
SCHEMBL3242737 0.83 NPC1 (0.61) NPC1HPGDKMT2ARAB9ASMN1; SMN2
SCHEMBL29429233 0.82 TOP1 (0.89) TOP1NPC1TERTSNCAALOX15
SCHEMBL109009 0.82 TOP1 (0.89) TOP1NPC1TERTSNCAALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1984883-B Substituted n-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies PROTEOTECH INC 2012-03-21 CN disclosed
US-20110104055-A1 SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES PROTEOTECH INC. 2011-05-05 US disclosed
US-7745490-B2 Substituted N-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies PROTEOTECH, INC. (US) 2010-06-29 US disclosed
US-7745490-B2 Substituted N-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies PROTEOTECH, INC. (US) 2010-06-29 US disclosed
US-7745490-B2 Substituted N-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies PROTEOTECH, INC. (US) 2010-06-29 US disclosed
EP-1751097-B1 SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES PROTEOTECH INC (US) 2009-12-30 EP disclosed
US-20090060838-A1 SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES PROTEOTECH INC. 2009-03-05 US disclosed
US-20090060838-A1 SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES PROTEOTECH INC. 2009-03-05 US disclosed
US-20090060838-A1 SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES PROTEOTECH INC. 2009-03-05 US disclosed
CN-1984883-A Substituted n-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies PROTEOTECH INC (US) 2007-06-20 CN disclosed
EP-1751097-A1 SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES Proteotech, Inc. (US) 2007-02-14 EP disclosed
US-20060199838-A1 Substituted N-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies PROTAMED, INC. 2006-09-07 US disclosed
WO-2005113489-A1 SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES PROTEOTECH, INC. (US) 2005-12-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090060838-A1 SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES IAPP, SNCA, BACE2 TOP1 4786/4885NPC1 1032/4885HPGD 4204/4885
US-20110104055-A1 SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES IAPP, SNCA, BACE2 TOP1 4768/4885NPC1 1010/4885HPGD 4117/4885
US-20060199838-A1 Substituted N-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies IAPP, SNCA, BACE2 TOP1 4778/4885NPC1 1016/4885HPGD 4171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.